AJMC® in the Press, March 31, 2023

The confirmatory trial showed limited side effects relative to physician's choice of chemotherapy.

On this episode of Managed Care Cast, we speak with the lead researcher from a study published in the May 2023 issue of The American Journal of Managed Care® about the impact of low-income subsidies on the uptake and equitable use of expensive orally administered antimyeloma therapy.

Roy S. Herbst, MD, PhD, deputy director of Yale Cancer Center and lead investigator for ADAURA, said the results erase any doubts about the use of osimertinib in early non–small cell lung cancer (NSCLC) for patients with EGFR mutations.

On this episode of Managed Care Cast, we feature several leaders in diversity, equity, and inclusion advancing health equity in their respective organization’s policy and practice initiatives.

With Medicare-aged Americans accounting for over 15% of the population and significant health care costs, stakeholders have leveraged various approaches, including the Medicare Current Beneficiary Survey, for estimating costs.

Combining talquetamab and daratumumab could create a synergy to get more from talquetamab to attack multiple myeloma.